

The Evolving Landscape in Molecular-Driven Investigational Therapies for Advanced Endometrial Cancer

An Industry Supported Symposium at the IGCS 2023 Annual Global Meeting Developed by Karyopharm in partnership with The GOG Foundation, Inc.


Seoul, South Korea

Monday, November 6, 2023



Faculty







Bradley J. Monk, MD, US Cancer Associates, Phoenix, Arizona, USA

Domenica Lorusso, MD, PhD, Catholic University of Rome and Fondazione Policlinico Gemelli IRCCS, Rome, Italy

Ritu Salani, MD, MS, UCLA Medical Center, Los Angeles, California, USA



Learning Objectives

• Discuss potential impact of endometrial cancer molecular profiling and understand what select molecular markers may mean for patients.

• Understand latest clinical trial data and emerging molecular-driven approaches for advanced endometrial cancer.

Review prospective directions for future treatment landscape.

This presentation is for scientific and educational purposes only and does not directly or indirectly promote or seek to promote Karyopharm's products, or any other drugs.



Agenda

Welcome & Introduction

Bradley J. Monk, MD, US Cancer Associates, Phoenix, Arizona, USA

Impact of Endometrial Cancer Molecular Profiling on Emerging Treatment Landscape

Bradley J. Monk, MD, US Cancer Associates, Phoenix, Arizona, USA All Faculty

Considerations for Maintenance Treatment in Advanced Endometrial Cancer

Bradley J. Monk, MD, US Cancer Associates, Phoenix, Arizona, USA All Faculty

Latest Molecular-Driven Clinical Trial Data in Front-Line Advanced Endometrial Cancer

Domenica Lorusso, MD, PhD, Catholic University of Rome and Fondazione Policlinico Gemelli IRCCS, Rome, Italy All Faculty

Future Perspectives on Personalized Medicine for Endometrial Cancer

Ritu Salani, MD, MS, UCLA Medical Center, Los Angeles, California, USA All Faculty

Closing Remarks

Bradley J. Monk, MD, US Cancer Associates, Phoenix, Arizona, USA

